Countdown to the Open: (MAIA) Just Hit the Top Spot On This Morning’s Radar

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Market Crux Puts (MAIA) Back At The Top Of Our Watchlist. Full Coverage Starts This Morning—Tuesday, January 27th, 2026 Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. (MAIA) Made An Approx. 93% Move In Under Two Months Since We Last Brought It To Our Readers In December Pull Up (MAIA) While It's Still Early… January 27, 2026 Countdown to the Open | (MAIA) Just Hit the Top Spot On This Morning's Radar Dear Reader, Recently, a pair of updates hit the wire on (MAIA)—and together, they help explain why the name has been back in sharp focus. First, Diamond Equity Research released an update to its research report on (MAIA), highlighting the company's late-stage progress and framing recent developments around its pivotal program—while reiterating its $10.27 valuation, which now suggests over 300% upside potential from (MAIA)'s recent $2.43 range. Shortly after, (MAIA) followed with a company-issued news release outlining targeted 2026 clinical milestones for its ateganosine (THIO) program, including its FDA Fast Track designation in NSCLC and the initiation of its THIO-104 Phase 3 trial in third-line NSCLC—along with additional updates tied to trial execution and development momentum. And it arrives at a moment when cancer research is increasingly focused on a new pressure point: the mechanisms that allow cancer cells to maintain their "immortality." Against that backdrop, (MAIA) has been drawing attention for an approach designed to target the protective caps on cancer chromosomes. This is just one of the reasons why (MAIA) is topping our watchlist this morning—Tuesday, January 27, 2026. Right now, (MAIA) is trending below $3, which can keep it off many screens—until new headlines pull it into focus. And with less than 30M shares listed as available to the public (per MarketWatch), its small float could witness the potential for big moves if demand begins to shift. That setup has already started to show up on the chart: (MAIA) made an approximate 200% move in the last three months, from $0.87 on November 20, 2025 to $2.78 on Friday, January 23, 2026. And analysts are still publishing valuations well above recent levels: Diamond Equity Research reiterated a $10.27 valuation on (MAIA), which suggests over 250% upside potential. Noble Capital Markets reiterated an Outperform rating with a $14.00 target on (MAIA), which suggests over 450% upside potential. While the global immunology market is projected to exceed $285B by 2034, a clinical-stage pioneer is capturing attention with a mechanism of action designed to target and disrupt the protective caps on cancer chromosomes. And that's before we get to what analysts are saying about where (MAIA) could land if the clinical story keeps progressing The Architect of Telomere Targeting MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company specifically engineered to discover and develop first-in-class therapies for cancer. Headquartered in Chicago, the firm focuses on the targeted immunotherapy space, specifically leveraging the biology of telomeres. Telomeres are the protective caps at the end of chromosomes that naturally shorten as cells age; however, roughly 85% to 90% of human cancers use the enzyme telomerase to maintain these caps, effectively becoming "immortal". The company's lead therapeutic candidate, ateganosine (also known as THIO), is a small molecule that represents a completely new class of treatment. By incorporating into the telomeric DNA of cancer cells, THIO induces rapid structural damage, leading to selective death in malignant cells while sparing healthy ones. This mechanism of action is particularly distinctive because it is designed to prime the immune system, potentially making standard checkpoint inhibitors significantly more effective in patients who have previously failed all other options. In a series of rapid-fire developments in late 2025, (MAIA) announced milestones that have placed it at the forefront of oncology. In December 2025, the company began treating patients in its pivotal Phase 3 clinical trial, marking a critical transition from research toward potential commercialization. Tapping into a $50B Immunotherapy Market The immunotherapy market is currently valued at approximately $50B, yet many patients with Non-Small Cell Lung Cancer (NSCLC) eventually develop resistance to current therapies. MAIA Biotechnology, Inc. (NYSE American: MAIA) is positioning ateganosine as the key to unlocking this resistance. By targeting telomeres, (MAIA) aims to convert "cold" tumors into "hot" tumors that are highly visible to the immune system, potentially expanding the efficacy of treatments like Libtayo. Pivotal Phase 3 Momentum and Execution On December 11, 2025, (MAIA) announced the first patient dosed in its THIO-104 Phase 3 pivotal trial. This study evaluates ateganosine in sequence with cemiplimab for patients with advanced NSCLC who have failed two prior lines of systemic therapy. This is a massive operational achievement, as Phase 3 trials represent the final clinical hurdle before regulatory approval. Data from the prior Phase 2 trial showed a median overall survival of 17.8 months, which is roughly 3x higher than the standard of care. Leadership Alignment and Intellectual Property Confidence within the company appears high, as leadership continued a consistent trend of insider buying throughout 2025. (MAIA) is led by CEO Vlad Vitoc, MD, MBA, who has over 20 years of oncology experience and has been involved in launching more than 20 compounds across 25+ tumor types. Furthermore, the company maintains a robust patent portfolio with 10 issued patents and 24 pending applications, providing exclusivity paths through at least 2041. A Broad Oncology Platform While NSCLC is the primary focus, ateganosine's potential use could extend across a broader range of oncology indications. The candidate already carries FDA Orphan Designations (ODDs) for several high-mortality diseases: Glioblastoma: A brain cancer market expected to grow from $2.2B to $3.2B. Hepatocellular Carcinoma (HCC): A dominant liver cancer histology with 0.8M annual mortality and $3.8B in sales. Small Cell Lung Cancer (SCLC): A deadly lung cancer variant with 0.3M mortality and $2.8B in sales. These designations provide seven years of U.S. market exclusivity upon regulatory FDA approval and access to tax credits—advantages that significantly strengthen (MAIA)'s long-term market positioning. Strategic Positioning As of late 2025, (MAIA)'s strategic approach to clinical recruitment has expanded globally, with regulatory approval to screen patients in Taiwan, Turkey, Georgia, and select European Medicines Agency countries. This international reach ensures a diverse and robust dataset for the THIO-104 trial. The company has managed a disciplined approach to development, recently announcing the completion of a $1M private placement following earlier funding rounds. The company is forecast to grow earnings and revenue by 53.9% and 114.5% per annum respectively over the coming years as it nears potential profitability. 7 Reasons Why (MAIA) is Topping Our Watchlist This Morning —Tuesday, January 27th, 2026 1. Recent Momentum: With an approximate 200% move inside the last three months ($0.87 to $2.78), (MAIA) has already shown it can draw momentum when the attention starts to turn. 2. Analyst Targets: With published valuations of $10.27 and a $14.00 target, (MAIA) has third-party expectations implying roughly +300% and +450% upside potential from its recent $2.43 range. 3. Small Float: With less than 30M shares listed as available to the public (per MarketWatch), (MAIA) can react sharply when attention and demand shift. 4. Late-Stage Phase: With a pivotal Phase 3 already dosing patients, (MAIA) is operating in a late-stage clinical setting where updates tend to matter more. 5. FDA Fast Track: With FDA Fast Track designation in NSCLC, (MAIA) has an added regulatory signal tied to its lead program's progress. 6. $50B Market: With checkpoint inhibitors generating roughly $50B in annual sales, (MAIA) is aligned with one of oncology's largest treatment categories through its clinical strategy and telomere-focused approach. 7. Fresh Potential Catalysts: With two recent wire updates, (MAIA) has re-entered sharp focus as new milestones and commentary stack up quickly. Pull Up (MAIA) While It's Still Early… (MAIA) is putting multiple attention-getting signals in one place: recent momentum that's already proven it can move when attention starts to change, a small float that has the potential for big moves if demand begins to shift, and a late-stage Phase 3 program where updates tend to carry more weight. Add in the FDA Fast Track designation in NSCLC, the connection to a $50B checkpoint inhibitor category, and two recent news releases that put the story back in circulation—and it's easy to see why (MAIA) keeps landing on serious screens. We have all eyes on (MAIA) this morning—Tuesday, January 27th, 2026. Take a look at (MAIA) while it's still early. Also, keep a lookout for my next update, it could be here very shortly. Sincerely, Gary Silver Managing Editor, Market Crux MarketCrux.com ("MarketCrux" or "MC" ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 01/27/2026 and ending on 01/27/2026 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Headline Media LLC has been paid fifty two thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://marketcrux.com/disclosure/maia-teK12/#details

Headline Media | 7901 4th Street N, Suite 300, St. Petersburg, FL 33702 Unsubscribe Update Profile | Constant Contact Data Notice Sent by gary@marketcrux.net